Wall Street is positive on Evogene Ltd (EVGN). On average, analysts give Evogene Ltd a Strong Buy rating. The average price target is $10.333, which means analysts expect the stock to climb 654.23% over the next twelve months. This average ranking earns Evogene Ltd an analyst rating of 73, which is better than 73% of the stock based on data compiled by InvestorsObserver.
Why are analyst ratings important?
Analysts know better than anyone the inner workings of the companies they follow, with the exception of the management of the companies. You can tell a lot about a company by studying the financial statements, but analysts ask questions on conference calls and understand the intricacies of each of the businesses they cover. Analysts understand how bad weather in any part of the world can disrupt supply chains or disrupt shopping habits. This allows traders to make decisions before a quarterly report that could be worse than expected.
InvestorsObserver aggregates the ratings of all analysts covering a given security, takes the average of these ratings, and then ranks the averages into percentiles. This provides a much better level of granularity than the three levels provided by traditional buy/hold/sell notations.
What’s going on with Evogene Ltd shares today?
Evogene Ltd (EVGN) stock is unchanged at 0% while the S&P 500 fell -0.69% at 2:54 p.m. on Wednesday March 30. EVGN is stable at $0.00 from the previous closing price of $1.37 on volume of 104,760 shares. Over the past year, the S&P 500 has risen 16.20% while the EVGN has fallen -70.54%. EVGN has lost -$0.69 per share over the past 12 months. Click here for the full Evogene Ltd stock report.
Stay in the know
Subscribe to our daily morning update newsletter and never miss market news, moves and more.